Dimension Therapeutics

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.

The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.
In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2013
Size (employees)
74 (est)-8%
Dimension Therapeutics was founded in 2013 and is headquartered in Cambridge, US

Key People at Dimension Therapeutics

Thomas Beck

Thomas Beck

President

Dimension Therapeutics Office Locations

Dimension Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1 Main Street

Dimension Therapeutics Data and Metrics

Dimension Therapeutics Financial Metrics

Dimension Therapeutics's revenue was reported to be $3.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

3.6 m

Net income (Q1, 2017)

(13.5 m)

EBIT (Q1, 2017)

(13.5 m)

Market capitalization (18-Aug-2017)

32.5 m

Cash (31-Mar-2017)

24 m
Dimension Therapeutics's current market capitalization is $32.5 m.
USDFY, 2015FY, 2016

Revenue

7.8 m11.5 m

Revenue growth, %

48%

R&D expense

2.8 m47.7 m

General and administrative expense

364 k12.8 m

Operating expense total

3.2 m60.5 m

EBIT

(3.2 m)(49.1 m)

EBIT margin, %

(41%)(428%)

Interest expense

(91 k)49 k

Interest income

(91 k)49 k

Net Income

(3.2 m)(49 m)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.1 m2.2 m2.4 m2.8 m3.6 m

R&D expense

10.4 m8.8 m11.2 m13.8 m13.7 m

General and administrative expense

2.3 m2.9 m3.2 m3.3 m3.4 m

Operating expense total

12.7 m11.7 m14.5 m17.1 m17.1 m

EBIT

(10.6 m)(9.5 m)(12.1 m)(14.3 m)(13.5 m)

EBIT margin, %

(516%)(432%)(511%)(519%)(374%)

Interest expense

(22 k)28 k6 k(26 k)

Interest income

(22 k)28 k6 k(26 k)

Net Income

(14.4 m)(13.5 m)
USDFY, 2015FY, 2016

Cash

127 m30.2 m

Accounts Receivable

143 k1.9 m

Inventories

2.7 m5.5 m

Current Assets

129.9 m85.3 m

PP&E

3.3 m8.4 m

Total Assets

133.3 m93.9 m

Accounts Payable

1.6 m2.4 m

Total Debt

1.1 m4.7 m

Current Liabilities

13.2 m20.6 m

Total Liabilities

33.9 m

Additional Paid-in Capital

156.8 m160.2 m

Retained Earnings

(51.2 m)(100.2 m)

Total Equity

105.6 m59.9 m

Debt to Equity Ratio

0 x0.1 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

1.3 x1.6 x
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

117 m104.7 m74.9 m24 m

Accounts Receivable

1.3 m1.3 m1.8 m2.4 m

Current Assets

120.9 m109.7 m98.5 m70.1 m

PP&E

6.2 m7.9 m8.7 m7.9 m

Total Assets

127.2 m117.6 m107.2 m78.2 m

Accounts Payable

2.2 m586 k1.4 m1.4 m

Current Liabilities

15 m14.8 m18.1 m17.4 m

Additional Paid-in Capital

157.3 m158.1 m159.2 m161.2 m

Retained Earnings

(60.7 m)(72.8 m)(87.2 m)(113.7 m)

Total Equity

96.6 m85.3 m72 m47.5 m

Financial Leverage

1.3 x1.4 x1.5 x1.6 x
USDFY, 2015FY, 2016

Net Income

(3.2 m)(49 m)

Depreciation and Amortization

716 k1.7 m

Accounts Receivable

(1 k)(1.7 m)

Inventories

(3 k)(2.7 m)

Accounts Payable

1 m814 k

Cash From Operating Activities

(192 k)(47.6 m)

Purchases of PP&E

(2.5 m)(6.7 m)

Cash From Investing Activities

(2.5 m)(54.3 m)

Cash From Financing Activities

4.7 m5.1 m

Interest Paid

82 k136 k
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(14.4 m)(13.5 m)

Accounts Receivable

2.1 m1.3 m1.3 m1.8 m2.4 m

Accounts Payable

775 k2.2 m586 k1.4 m1.4 m
USDY, 2017

Revenue/Employee

46.7 k

Financial Leverage

1.6 x

Dimension Therapeutics Market Value History

Traffic Overview of Dimension Therapeutics

Dimension Therapeutics Online and Social Media Presence

Dimension Therapeutics Company Life and Culture

You may also be interested in